



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/535, 31/445	A1	(11) International Publication Number: WO 98/24446 (43) International Publication Date: 11 June 1998 (11.06.98)															
(21) International Application Number: PCT/EP97/06692 (22) International Filing Date: 25 November 1997 (25.11.97) (30) Priority Data: <table border="0"> <tr> <td>9625051.9</td> <td>2 December 1996 (02.12.96)</td> <td>GB</td> </tr> <tr> <td>9701459.1</td> <td>24 January 1997 (24.01.97)</td> <td>GB</td> </tr> <tr> <td>9713715.2</td> <td>27 June 1997 (27.06.97)</td> <td>GB</td> </tr> <tr> <td>9717425.4</td> <td>15 August 1997 (15.08.97)</td> <td>GB</td> </tr> <tr> <td>9721193.2</td> <td>7 October 1997 (07.10.97)</td> <td>GB</td> </tr> </table> (71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BAKER, Raymond [GB/GB]; BBSRC, Polaris House, North Star Avenue, Swindon SN2 1UH (GB). CURTIS, Neil, Roy [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). ELLIOTT, Jason, Matthew [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). HARRISON, Timothy [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). HOLLINGWORTH, Gregory, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). JACKSON, Philip,		9625051.9	2 December 1996 (02.12.96)	GB	9701459.1	24 January 1997 (24.01.97)	GB	9713715.2	27 June 1997 (27.06.97)	GB	9717425.4	15 August 1997 (15.08.97)	GB	9721193.2	7 October 1997 (07.10.97)	GB	Stephen [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). KULAGOWSKI, Janusz, Jozef [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). RUPNIAK, Nadia, Melanie [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). SEWARD, Eileen, Mary [IE/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). SWAIN, Christopher, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). WILLIAMS, Brian, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: HISCOCK, Ian; Merck & Co., Inc., European Patent Dept., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
9625051.9	2 December 1996 (02.12.96)	GB															
9701459.1	24 January 1997 (24.01.97)	GB															
9713715.2	27 June 1997 (27.06.97)	GB															
9717425.4	15 August 1997 (15.08.97)	GB															
9721193.2	7 October 1997 (07.10.97)	GB															
(54) Title: USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS (57) Abstract <p>The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.</p>																	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS

This invention relates to the treatment or prevention of movement
5 disorders by the administration of a specific class of NK-1 receptor
antagonists.

Diseases of the extrapyramidal motor systems cause either a loss of
movement (akinesia) accompanied by an increase in muscle tone (rigidity)
or abnormal involuntary movements (dyskinesias) often accompanied by a
10 reduction in muscle tone. The akinetic-rigid syndrome called
parkinsonism, and the dyskinesias represent opposite ends of the
spectrum of movement disorders (for review see C. D. Marsden in *Oxford
Textbook of Medicine*, 3rd Edition, Oxford University Press, 1996, vol. 3,
pages 3998-4022).

15 Treatment of akinetic-rigid conditions such as parkinsonism
typically involves the use of levodopa, anticholinergics or dopamine
agonists. Levodopa is converted into dopamine in the brain by the enzyme
dopa decarboxylase. However, this enzyme is also present in the gut wall,
liver, kidney and cerebral capillaries, thus the peripheral formation of
20 levodopa metabolites may give rise to side-effects such as nausea,
vomiting, cardiac dysrhythmias and postural hypotension. This
peripheral decarboxylation is largely prevented by the addition of a
selective extracerebral decarboxylase inhibitor, such as carbidopa or
benserazide, which themselves do not penetrate the brain. Levodopa
25 combined with carbidopa (SINEMET™) or benserazide (MADOPAR™) is
now the treatment of choice when levodopa is indicated. Even then, this
combination therapy may be associated with side-effects such as
dyskinesias and psychiatric disturbances.

An anticholinergic such as benzhexol or orphenadrine may be used,
30 however, anticholinergics cause peripheral parasympathetic blockade
which may cause dry mouth, blurred vision and constipation, and they

may also precipitate glaucoma, urinary retention and a toxic confusional state.

Dopamine agonists such as bromocriptine (PARLODEL™), lisuride and pergolide (CELANCE™) act directly on dopamine receptors and have a
5 similar side-effect profile to levodopa.

The dyskinesias, notably tremor, chorea, myoclonus, tics and dystonias, are treated with a variety of pharmacological agents. Thus, for example, tremor may be treated with benzodiazepines such as diazepam; chorea may be treated with diazepam, a phenothiazide or haloperidol, or
10 tetrabenazine; tics may be controlled with neuroleptics such as haloperidol or pimozide; and dystonias tend to be treated with levodopa, benzodiazepines such as diazepam, anticholinergics such as benzhexol, phenothiazines and other neuroleptics such as haloperidol, and tetrabenazine.

15 Treatment of psychotic disorders with neuroleptic agents, such as haloperidol may be at the expense of a number of side-effects, including extrapyramidal symptoms, acute dystonias, tardive dyskinesias, akathisia, tremor, tachycardia, drowsiness, confusion, postural hypotension, blurring of vision, precipitation of glaucoma, dry mouth,
20 constipation, urinary hesitance and impaired sexual function.

Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Examples of conditions in which substance P has been
25 implicated include disorders of the central nervous system such as anxiety, depression and psychosis (see, for instance, International (PCT) patent specification Nos. WO 95/16679, WO 95/18124 and WO 95/23798).

More recently, International (PCT) patent specification No. WO 96/24353 (published 15th August 1996) suggests that a more efficacious
30 and safe treatment of psychiatric disorders would be achieved using a

combination of a tachykinin antagonist and a serotonin agonist or selective serotonin reuptake inhibitor (SSRI).

NK-1 receptor antagonists are described in published European Patent Specification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 5 0 482 539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577 394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; and in 10 International Patent Specification Nos. 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14113, 93/18023, 93/19064, 93/21155, 93/21181, 93/23380, 93/24465, 94/01402, 94/02461, 94/03429, 15 94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129, 95/19344, 20 95/20575, 95/21819, 96/22525, 95/23798, 95/26338, 95/28418, 95/30674, 95/30687, 96/05193, 96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/19084, 97/19942 and 97/21702; and in 25 British Patent Specification Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293 169, and 2 302 689.

In view of the short-comings of existing therapy, there is a need for new, safe and effective treatment for movement disorders.

The present invention provides the use of a CNS penetrant NK-1 30 receptor antagonist in an oral medicament for the treatment of movement disorders. The compounds of this class advantageously exhibit a rapid

onset of action and a reduced side-effect profile when compared against conventional agents used for the treatment of extrapyramidal movement disorders and other types of movement disorders (e.g. idiopathic Parkinson's disease, secondary Parkinson's disease, Huntingdon's disease, dystonia, chorea, tics, myoclonus and athetosis).

In particular, the present invention provides a means for the identification of NK-1 receptor antagonists which would be effective in an oral medicament for the treatment of movement disorders with or without combination with conventional agents currently in use. The aforementioned patent specifications which describe NK-1 receptor antagonists provide no reliable method for the identification of such compounds.

The exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention enables the treatment of movement disorders, without the need for concomitant therapy.

Furthermore, the exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention results in a rapid onset of action.

The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined) for the manufacture of a medicament adapted for oral administration for the treatment or prevention of movement disorders.

The present invention also provides a method for the treatment or prevention of movement disorders, which method comprises the oral administration to a patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined).

In a further aspect of the present invention, there is provided an oral pharmaceutical composition for the treatment of movement disorders which comprises an orally active, long acting, CNS-penetrant NK-1

receptor antagonist (as hereinafter defined), together with a pharmaceutically acceptable carrier or excipient.

There exists a patient population in whom dyskinesias are inadequately treated with existing neuroleptic therapy. Furthermore,
5 some patients may be adversely affected by the side-effects of neuroleptic drugs.

The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the
10 treatment or prevention of dyskinesias in a patient who is non-responsive to neuroleptic agents, or for whom neuroleptic agents are contraindicated.

The present invention also provides a method for the treatment or prevention of dyskinesias in a patient who is non-responsive to neuroleptic agents, or for whom neuroleptic agents are contraindicated, which method
15 comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

Whilst it is envisaged that an orally active, long acting, CNS-penetrant NK-1 receptor antagonist will be useful alone in the treatment
20 of movement disorders, it will be appreciated that a combination of a conventional antiparkinsonian drug with a NK-1 receptor antagonist may provide an enhanced effect in the treatment of akinetic-rigid disorders such as parkinsonism. Such a combination may enable a lower dose of the antiparkinsonian agent to be used without compromising the efficacy of
25 the antiparkinsonian agent, thereby minimising the risk of adverse side-effects.

Thus, according to a further aspect of the present invention there is provided the use of a NK-1 receptor antagonist and an antiparkinsonian agent for the manufacture of a medicament for the treatment or
30 prevention of akinetic-rigid disorders.

The present invention also provides a method for the treatment or prevention of akinetic-rigid disorders, which method comprises administration to a patient in need of such treatment of an amount of a NK-1 receptor antagonist and an amount of an antiparkinsonian agent, such that together they give effective relief.

In a further aspect of the present invention, there is provided a pharmaceutical composition comprising a NK-1 receptor antagonist and an antiparkinsonian agent, together with at least one pharmaceutically acceptable carrier or excipient.

It will be appreciated that the NK-1 receptor antagonist and the antiparkinsonian agent may be present as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention of akinetic-rigid disorders. Such combined preparations may be, for example, in the form of a twin pack.

In a further or alternative aspect of the present invention, there is therefore provided a product comprising a NK-1 receptor antagonist and an antiparkinsonian agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of akinetic-rigid disorders.

It will be further appreciated that a combination of a conventional neuroleptic drug with a NK-1 receptor antagonist may provide an enhanced effect in the treatment of dyskinesias. Such a combination may enable a lower dose of the neuroleptic agent to be used without compromising the efficacy of the neuroleptic agent, thereby minimising the risk of adverse side-effects. A yet further advantage of such a combination is that, due to the action of the NK-1 receptor antagonist, adverse side-effects caused by the neuroleptic agent such as acute dystonias, dyskinesias, akathisia and tremor may be reduced or prevented.

Thus, according to a further aspect of the present invention there is provided the use of a NK-1 receptor antagonist and a neuroleptic agent for

the manufacture of a medicament for the treatment or prevention of dyskinesias.

The present invention also provides a method for the treatment or prevention of dyskinesias, which method comprises administration to a
5 patient in need of such treatment of an amount of a NK-1 receptor antagonist and an amount of a neuroleptic agent, such that together they give effective relief.

In a further aspect of the present invention, there is provided a pharmaceutical composition comprising a NK-1 receptor antagonist and a
10 neuroleptic agent, together with at least one pharmaceutically acceptable carrier or excipient.

It will be appreciated that the NK-1 receptor antagonist and the neuroleptic agent may be present as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention
15 of dyskinesias. Such combined preparations may be, for example, in the form of a twin pack.

In a further or alternative aspect of the present invention, there is therefore provided a product comprising a NK-1 receptor antagonist and an neuroleptic agent as a combined preparation for simultaneous, separate
20 or sequential use in the treatment or prevention of dyskinesias.

It will be appreciated that when using a combination of the present invention, the NK-1 receptor antagonist and the antiparkinsonian or neuroleptic agent may be in the same pharmaceutically acceptable carrier and therefore administered simultaneously. They may be in separate
25 pharmaceutical carriers such as conventional oral dosage forms which are taken simultaneously. The term "combination" also refers to the case where the compounds are provided in separate dosage forms and are administered sequentially. Therefore, by way of example, the antiparkinsonian or neuroleptic agent may be administered as a tablet
30 and then, within a reasonable period of time, the NK-1 receptor antagonist may be administered either as an oral dosage form such as a tablet or a

fast-dissolving oral dosage form. By a "fast-dissolving oral formulation" is meant, an oral delivery form which when placed on the tongue of a patient, dissolves within about 10 seconds.

As used herein, the term "movement disorders" includes akinesias
5 and akinetic-rigid syndromes, dyskinesias and medication-induced parkinsonism (such as neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremor). Examples of "akinetic-rigid
10 syndromes" include Parkinson's disease, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonism-ALS dementia complex and basal ganglia calcification. Examples of "dyskinesias" include tremor (including rest tremor, postural tremor and intention tremor),
15 chorea (such as Sydenham's chorea, Huntington's disease, benign hereditary chorea, neuroacanthocytosis, symptomatic chorea, drug-induced chorea and hemiballism), myoclonus (including generalised myoclonus and focal myoclonus), tics (including simple tics, complex tics and symptomatic tics), and dystonia (including generalised dystonia such
20 as idiopathic dystonia, drug-induced dystonia, symptomatic dystonia and paroxymal dystonia, and focal dystonia such as blepharospasm, oromandibular dystonia, spasmodic dysphonia, spasmodic torticollis, axial dystonia, dystonic writer's cramp and hemiplegic dystonia).

Another "movement disorder" which may be treated according to the
25 present invention is Gilles de la Tourette's syndrome, and the symptoms thereof.

As used herein, the term "treatment" refers both to the treatment and to the prevention or prophylactic therapy of the aforementioned conditions.

30 Preferred NK-1 receptor antagonists for use in the present invention are selected from the classes of compounds described in

European Patent Specification No. 0 577 394, and International Patent Specification Nos. 95/08549, 95/18124, 95/23798 and 96/05181, and International Patent Application No. PCT/GB97/01630. The preparation of such compounds is fully described in the aforementioned publications.

5 Particularly preferred NK-1 receptor antagonists of use in the present invention include:

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

10 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

15 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;

20 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

25 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxyphosphoryl-1H-1,2,4-triazolo)methyl)morpholine;

2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine;

30 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N-dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;

(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

5 or a pharmaceutically acceptable salt thereof.

Full descriptions of the preparation of the NK-1 receptor antagonists which may be employed in the present invention may be found in the references cited herein.

Suitable antiparkinsonian agents of use in combination with a NK-1
10 receptor antagonist include levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt) and trihexyphenidyl (benzhexol) hydrochloride, and dopamine agonists such as alentemol, bromocriptine, fenoldopam, lisuride,
15 naxagolide, pergolide and pramipexole. It will be appreciated that the dopamine agonist may be in the form of a pharmaceutically acceptable salt, for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate. Lisuride and pramipexol are commonly used in a non-salt form.

20 Suitable neuroleptic agents of use in combination with a NK-1 receptor antagonist include the phenothiazine, thioxanthene, heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine and indolone classes of neuroleptic agent. Suitable examples of phenothiazines include chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine,
25 perphenazine and trifluoperazine. Suitable examples of thioxanthenes include chlorprothixene and thiothixene. An example of a dibenzazepine is clozapine. An example of a butyrophenone is haloperidol. An example of a diphenylbutylpiperidine is pimozide. An example of an indolone is molindolone. Other neuroleptic agents include loxapine, sulpiride and
30 risperidone. It will be appreciated that the neuroleptic agents when used in combination with a NK-1 receptor antagonist may be in the form of a

pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, 5 thiothixene hydrochloride, haloperidol decanoate, loxapine succinate and molindone hydrochloride. Perphenazine, chlorprothixene, clozapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form.

Suitable pharmaceutically acceptable salts of the NK-1 receptor 10 antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts 15 of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group. Where the compound carries an acidic group, for example a carboxylic acid group, the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, 20 such as the sodium, potassium and calcium salts thereof.

Suitable pharmaceutically acceptable salts of the antiparkinsonian and neuroleptic agents used in combination with a NK-1 receptor antagonist according to the present invention include those salts described above in relation to the salts of NK-1 receptor antagonists.

25 Preferably the compositions containing an NK-1 receptor antagonist of use according to the present invention are in unit dosage forms such as tablets, pills, capsules, wafers and the like. Additionally, the NK-1 receptor antagonists of use according to the present invention may be presented as granules or powders for extemporaneous formulation as 30 volume defined solutions or suspensions. Alternatively, the NK-1 receptor antagonists of use according to the present invention may be presented in

ready-prepared volume defined solutions or suspensions. Preferred forms are tablets and capsules.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional
5 tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.

10 When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage
15 forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage
20 component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials
25 including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and
30 flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar

pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

5 Compositions of the present invention may also be administered via the buccal cavity using conventional technology, for example, absorption wafers.

Compositions in the form of tablets, pills, capsules or wafers for oral administration are particularly preferred.

10 The present invention further provides a process for the preparation of a pharmaceutical composition comprising a NK-1 receptor antagonist and an antipsychotic agent, which process comprises bringing a NK-1 receptor antagonist and an antipsychotic agent, into association with a pharmaceutically acceptable carrier or excipient.

15 When administered in combination, either as a single or as separate pharmaceutical composition(s), the NK-1 receptor antagonist and an antipsychotic agent are presented in a ratio which is consistent with the manifestation of the desired effect. In particular, the ratio by weight of the NK-1 receptor antagonist and the antipsychotic agent will suitably be
20 between 0.001 to 1 and 1000 to 1, and especially between 0.01 to 1 and 100 to 1.

 A minimum dosage level for the NK-1 receptor antagonist is about 1mg per day, preferably about 5mg per day and especially about 10mg per day. A maximum dosage level for the NK-1 receptor antagonist is about
25 1500mg per day, preferably about 1000mg per day and especially about 500mg per day. The compounds are administered one to three times daily, preferably once or twice a day, and especially once a day.

 A minimum dosage level for the antiparkinsonian agent will vary depending upon the choice of agent, but is typically about 0.05mg per day
30 for the most potent compounds or about 20mg per day for less potent compounds. A maximum dosage level for the antipsychotic agent is

typically 30mg per day for the most potent compounds or 500mg per day for less potent compounds. The compounds are administered one to three times daily, preferably once or twice a day, and especially once a day.

A minimum dosage level for the neuroleptic agent will vary
5 depending upon the choice of agent, but is typically about 0.5mg per day for the most potent compounds or about 20mg per day for less potent compounds. A maximum dosage level for the neuroleptic agent is typically 30mg per day for the most potent compounds or 200mg per day for less
10 potent compounds. The compounds are administered one to three times daily, preferably once or twice a day, and especially once a day.

It will be appreciated that the amount of the NK-1 receptor antagonist required for use in the treatment or prevention of movement disorders will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the
15 condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.

When used in combination, it will be appreciated that the amount of the NK-1 receptor antagonist and the antiparkinsonian or neuroleptic agent required for use in the treatment or prevention of movement
20 disorders will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.

25 Two compounds of use in the present invention which are described in International Patent Application No. PCT/GB97/01630 may be prepared according to the following methods:

PREPARATION 1

(2S)-1-tert-Butoxycarbonyl-2-phenylpiperidin-3-one

Dimethyl sulfoxide (20.80ml, 22.90g, 29.3mmol) in dichloromethane (75ml) was added dropwise to a cooled (-70°C) solution of oxalyl chloride (13.95ml, 20.30g, 160mmol) in dichloromethane (350ml). The mixture was stirred at -70°C for 15 minutes, then (2S,3S)-1-tert-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared by the method described in European Patent Specification number 0 528 495-A; 36.91g, 133mmol) in dichloromethane (150ml) was added dropwise. The mixture was stirred at -70 °C for 20 minutes, then allowed to warm to -30°C. The mixture was cooled to -50 °C and triethylamine (55.95ml, 40.45g, 400mmol) was added slowly. The mixture was allowed to warm to 0°C and diluted with ice-cooled dichloromethane (250ml). The mixture was washed with ice cold aqueous citric acid solution (5%, 2x300ml) and water (300ml), dried (MgSO₄), and the solvent was evaporated under reduced pressure to give the title compound as a yellow oil (42.3g), which was used immediately without further purification. ¹H NMR (250MHz, CDCl₃) δ 7.5-7.3 (5H, m), 5.8 (1H, br s), 4.2 (1H, br s), 3.4 (1H, m), 2.6 (2H, m), 2.0 (2H, m), and 1.54 (9H, s).

PREPARATION 2

(2S,3R)-1-tert-Butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine

A solution of 3-(chloromagnesio)-2-(phenoxymethyl)-1-propene in THF (0.91M, 3ml) (Louw *et. al.*, *Tetrahedron*, 48, 6087-6104, 1992, prepared from 2.74mmol of 3-chloro-2-(phenoxymethyl)-1-propene) was slowly added to a solution of (2S)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one (Preparation 1) in THF (3ml). The mixture was stirred at room temperature for 1 hours, then saturated aqueous ammonium chloride (20ml) was added and the mixture was extracted with ethyl acetate (20ml). The organic phase was washed with brine, dried (MgSO₄) and the

solvent was evaporated under reduced pressure . The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (100:0 increasing to 80:20) to give the title compound. ¹H NMR (360MHz, CDCl₃) δ 7.48 (2H, d, *J*=6.9 Hz), 7.35-7.2 (6H, m), 6.9-6.88 (3H, m), 5.4 (1H, s), 5.15 (2H, d, *J*=13.7 Hz), 4.61 (2H, s), 4.11 (2H, m), 3.17 (1H, m), 2.66 and 2.59 (2H, AB d, *J*=14.0 Hz), 1.95 (2H, m), 1.79 (2H, m), and 1.36 (9H, s). *m/z* (ES⁺) 424 (M+1).

PREPARATION 3

10 (5*R*,6*S*)-3-Methylene-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

To a cooled(-80 °C) solution of (2*S*,3*R*)-1-*tert*-butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine (Preparation 2, 1.53g, 3.62mmol) in THF (20ml) was added *n*-butyl lithium (2.5M in hexanes, 1.45ml, 3.62mmol) followed by a solution of zinc chloride (0.5M in THF, 7.24ml, 3.62mmol). The solution was allowed to warm to room temperature and tetrakis(triphenylphosphine)palladium (0) (0.23g, 0.2mmol) was added. The mixture was degassed with bubbling nitrogen and heated under reflux for 16 hours. The mixture was cooled and the solvent was evaporated under reduced pressure. The residue was partitioned between ethyl acetate and 2M sodium hydroxide. The organic phase was washed with saturated brine, dried (MgSO₄) and purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%).

25 Evaporation of the fractions gave (6*S*,5*R*)-3-methylene-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane. ¹H NMR (360MHz, CDCl₃) δ 7.58 (2H, d, *J*=8.4 Hz), 7.32-7.21 (3H, m), 5.23 (1H, s), 5.06 (1H, m), 4.97 (1H, m), 4.39 (2H, AB d, *J*=13.3 Hz), 3.99 (1H, dd, *J*=13.3, 4.48 Hz), 2.83 (1H, ABd *J*=15.5 Hz), 2.7 (1H, td *J*=12.5, 3.93 Hz), 2.5 (1H, ABd, *J*=15.4 Hz), 2.15 (2H, td, *J*=12., .4 Hz), 1.69 (2H, m), and 1.46 (9H, s). *m/z* (ES⁺) 329 (M+2H-^tBuOCO).

PREPARATION 4

(5*R*,6*S*)-3-Keto-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

Through a cooled (-80 °C) solution of (5*R*,6*S*)-3-methylene-6-phenyl-
5 1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 3; 0.665g)
in dichloromethane (5ml) and methanol (5ml) was bubbled a mixture of
ozone and oxygen for 45 minutes. After the solution had been purged with
nitrogen, dimethyl sulphide (0.5ml) was added and then stirred under
nitrogen at room temperature for 16 hours. The solvent was removed *in*
10 *vacuo* and the residue partitioned between ethyl acetate and water. The
organic phase was dried (MgSO₄), evaporated and the residue purified by
chromatography on a column containing silica gel (eluting with hexane
containing increasing proportions of ethyl acetate between 0% to 10%).
Evaporation of the fractions gave the title compound. ¹H NMR (250MHz,
15 CDCl₃) δ 7.58 (2H, d, *J*=6.2 Hz), 7.37-7.26 (3H, m), 5.3 (1H, s), 4.15 and
4.09 (2H, AB d, *J*=17.4 Hz), 3.97 (1H, m), 2.80 (1H, td, *J*=12.9, 4.0 Hz),
2.74 and 2.48 (2H, ABd, *J*=18.1 Hz), 2.29 (2H, m), 1.88-1.63 (2H, m), and
1.44 (9H, s). *m/z* (ES⁺) 332 (M+1).

20

PREPARATION 5

(5*R*,6*S*)-3-Trifluoromethylsulfonyloxy-6-phenyl-1-oxa-7-(*tert*- butoxycarbonyl)aza-spiro[4.5]dec-3-ene

To a cooled (-80 °C) solution of 1M sodium hexamethyldisilazide
(0.38ml, 0.38mmol) in THF was added a solution of (5*R*,6*S*)-3-keto-6-
25 phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 4;
0.105mg, 0.319mmol) in THF (3ml). The solution was stirred for 1 hours
at -80°C then a solution of 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-
chloropyridine (0.163g, 0.415mmol) in THF (3ml) was added. The solution
was stirred at -80°C for 30 minutes then at room temperature for 30
30 minutes before being quenched by addition of saturated ammonium
chloride solution and ethyl acetate. The dried (MgSO₄) organic phase was

purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%). Evaporation of the fractions gave the title compound. ¹H NMR (360MHz, CDCl₃) δ 7.4 (2H, d, *J*=7.3 Hz), 7.3-7.22 (3H, m), 6.01 (1H, t, *J*=2.13 Hz), 5.13 (1H, s), 4.56 and 4.26 (2H, ABdd, *J*=12.4, 1.97 Hz), 4.10 (1H, dt, *J*=12.6, 4.22 Hz), 3.00 (1H, m), 2.28-2.04 (2H, m), 1.88-1.76 (2H, m), and 1.37 (9H, s). *m/z* (ES⁺) 464 (M+1).

PREPARATION 6

10 (5*R*,6*S*)-3-Trimethylstannyl-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

To a degassed solution of (5*R*,6*S*)-3-trifluoromethylsulfonyloxy-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 5; 0.482g, 1.04mmol), lithium chloride (0.264g, 6.25mmol), lithium carbonate (0.076g) and hexamethyl distannane(0.96g, 2.9mmol) in THF (10ml) was added triphenylphosphine palladium (0) (0.06g). The solution was degassed and then heated at 60°C for 5 hours under nitrogen. Water (20ml) and ethyl acetate (20ml) were added and the dried organic phase was purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%). Evaporation of the fractions gave the title compound as a crystalline solid. ¹H NMR (360MHz, CDCl₃) δ 7.25 (2H, d, *J*=7.3 Hz), 7.1-7.0 (3H, m), 5.83 (1H, t, *J*=2.5 Hz), 4.78 (1H, s), 4.48 and 4.02 (2H, dd, *J*=12.9, 2.3 Hz), 3.96 (1H, dd, *J*=6.16, 13.4 Hz), 2.95 (1H, td, *J*=13.3, 4.5 Hz), 1.84 (1H, m), 1.68 (1H, m), 1.60 (2H, m), 1.19 (9H, s), and 0.0 (6H, s).

PREPARATION 7

(2*S*,3*R*)-1-*tert*-Butoxycarbonyl-3-(3-hydroxypropyn-1-yl)-2-phenylpiperidin-3-ol

30 O-Trimethylsilylpropargyl alcohol (24.51ml, 20.47g, 160ml) was added slowly to a cooled (-10°C) solution of ethylmagnesium bromide (1M

in tetrahydrofuran, 160ml, 160mmol). The mixture was stirred at 0°C for 20 minutes, then at room temperature for 2 hours. The mixture was cooled to -10°C and a solution of (2*S*)-1-*tert*-butoxycarbonyl-2-phenylpiperidin-3-one (Preparation 1; 42.3g) in tetrahydrofuran (200ml) was added dropwise over 30 minutes. (Internal temperature below -5°C). The mixture was stirred at room temperature for 14 hours, poured into water (300ml) and saturated aqueous ammonium chloride (300ml) and extracted with ethyl acetate (2x300ml). The combined organic fractions were washed with brine (300ml), dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (500ml) and a solution of tetrabutylammonium fluoride (1M in THF, 160ml, 160mmol) was added dropwise. The mixture was stirred at room temperature for 30 minutes, water (300ml) was added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (2x300ml) and the combined organic fractions were washed with water (300ml) and brine (300ml), dried (MgSO₄) and the solvent was evaporated under reduced pressure to give the crude title compound as an orange oil (45g). The crude material was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 25:75) to give the title compound as an amber oil (32.2g). ¹H NMR (CDCl₃) δ 7.53-7.55 (2H, m), 7.19-7.35 (3H, m), 5.56 (1H, s), 4.27 (2H, s), 3.99-4.03 (1H, m), 3.25 (1H, br s), 2.77-2.81 (1H, m), 2.77 (1H, br s), 2.12-2.20 (1H, m), 1.91-1.99 (2H, m), 1.77-1.83 (1H, m), and 1.39 (9H, s).

25

PREPARATION 8

2-Bromo-4-(trifluoromethoxy)phenol

To a cooled (0 °C) solution of 4-trifluoromethoxyphenol (35.6g, 0.2mol) in chloroform (280ml) was added dropwise a solution of bromine (32g, 0.2mol) in chloroform (50ml). The solution was stirred at 0°C for 1 hour and at room temperature for 2 hours. Dichloromethane (200ml) and water (400ml) were added and the organic phase was washed further with

water(400ml), brine (200ml) and dried (MgSO₄). The solvent was removed and the residue was purified by distillation at reduced pressure to give the title compound. ¹H NMR (250MHz, CDCl₃) δ 7.38 (1H, d, *J*=2.1 Hz), 7.13 (1H, dd, *J*=9.1, 2.1 Hz), 7.03 (1H, d, *J*=9.1 Hz), and 5.53 (1H, s).

5

PREPARATION 9

2-Benzyloxy-5-(trifluoromethoxy)bromobenzene

2-Bromo-4-(trifluoromethoxy)phenol (Preparation 8; 5g, 20mmol) was dissolved in *N,N*-dimethylformamide (60ml), and potassium carbonate (5.4g, 40mmol) was added, followed by benzyl bromide (3.5ml, 30mmol), and the reaction was stirred at ambient temperature for 15 hours. The reaction was diluted with water (150ml) and extracted into ethyl acetate (3x60ml). The combined organic fractions were washed with water (100ml), brine (100ml), dried (MgSO₄) and evaporated *in vacuo*. Purification on silica, eluting with 2% and 5% ethyl acetate in hexane gave the title compound as a clear oil (6.7g, 96%). ¹H NMR (250MHz, CDCl₃) δ 5.47 (2H, s), 7.23 (1H, d, *J*=9 Hz), 7.43 (1H, dd *J*=8.2, 2.9 Hz), and 7.75 (6H, m).

20

PREPARATION 10

Z-(2*S*,3*R*)-1-*tert*-Butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol

Palladium on calcium carbonate, poisoned with lead (Lindlar catalyst, 2g) was added to a solution of (2*S*,3*R*)-1-*tert*-butoxycarbonyl-3-(3-hydroxypropyn-1yl)-2-phenylpiperidin-3-ol (Preparation 7; 32g, 96.6mmol) in ethyl acetate (300ml) and the mixture was stirred under hydrogen (1 atmosphere) for 4 hours. The mixture was filtered and the solvent was evaporated under reduced pressure to give the title compound as an oil (32g, 100%). ¹H NMR (360MHz, CDCl₃) δ 7.42 (2H, d, *J*=7.6 Hz), 7.35-7.25 (3H, m), 5.83 (1H, d, *J*=12.3 Hz), 5.68 (1H, dt, *J*=12.3, 6.0 Hz), 5.06 (1H, s),

30

4.27 (1H, m), 4.12 (2H, m), 3.32 (1H, m), 3.13 (1H, s), 2.28 (1H, t, $J=5.9$ Hz), 2.02 (1H, m), 1.92-1.78 (3H, m), and 1.32 (9H, s). m/z (ES⁺) 334 (M+1).

PREPARATION 11

5 (5R,6S)-6-Phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

Diethylazodicarboxylate (18.2ml, 115mmol) in THF (100ml) was added dropwise to a solution of *Z*-(2*S*,3*R*)-1-*tert*-butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol (Preparation 10; 32g, 96mmol) and triphenylphosphine (30.2g, 115mmol) in THF (700ml). The mixture was stirred at 0°C for 30 minutes then at room temperature for 1.5 hours. The solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (95:5 increasing to 80:20) to give the title compound as a colorless solid (23.4g, 77%). ¹H NMR (CDCl₃) δ 7.45 (2H, d, $J=7.4$ Hz), 7.27 (2H, t, $J=7.4$ Hz), 7.20 (1H, t, $J=7.4$ Hz), 6.03 (1H, dt, $J=6.1, 2.0$ Hz), 5.68 (1H, dt, $J=6.1, 2.0$ Hz), 5.06 (1H, s), 4.61 (1H, dt, $J=13.1, 2.0$ Hz), 4.32 (1H, dt, $J=13.1, 2.0$ Hz), 4.08 (1H, m), 3.05 (1H, m), 2.05 (1H, m), 1.75 (3H, m), and 1.37 (9H, s). m/z (ES⁺) 316 (M+1).

20 PREPARATION 12

2-Benzoyloxy-5-(trifluoromethoxy)benzene

Benzyl bromide (66.17ml, 95.35g, 0.56mol) was added to a mixture of 4-(trifluoromethoxy)phenol (90.26g, 0.51mol) and potassium carbonate (140.97g, 1.2mol) in dimethylformamide (160ml) and the mixture was stirred at room temperature for 72 hours. The mixture was poured into water (1.5 l) and extracted with ethyl acetate (3x500ml). The combined organic fractions were washed with aqueous sodium carbonate (saturated, 500ml), dried (MgSO₄) and the solvent was evaporated under reduced pressure to give the title compound as a colorless solid (133.5g, 99%). ¹H NMR (360MHz, CDCl₃) δ 7.39 (5H, m), 7.14 (2H, d, $J=9.0$ Hz), 6.95 (2H, d, $J=9.0$ Hz), and 5.05 (2H, s).

PREPARATION 13

2-Benzoyloxy-5-(trifluoromethoxy)iodobenzene

Iodine (71.96g, 0.28mol) in chloroform was added dropwise to a
5 mixture of 2-benzoyloxy-5-(trifluoromethoxy)benzene (Preparation 12,
73.06g, 0.27mol) and silver trifluoroacetate (71.57g, 0.32mol) in
dichloromethane and the mixture was stirred at room temperature for 18
hours. The mixture was filtered through celite, washed with aqueous
sodium thiosulfate (5%, 2x2 l), dried (MgSO₄) and the solvent was
10 evaporated under reduced pressure. The residue was purified by flash
column chromatography on silica gel, eluting with hexane/ethyl acetate, to
give the title compound as a colorless oil (108.03g), containing 11%
unreacted 2-benzoyloxy-5-(trifluoromethoxy)iodobenzene. ¹H NMR
(360MHz, CDCl₃) δ 7.67 (1H, d, *J*=2.8 Hz), 7.40 (5H, m), 7.16 (1H, dd,
15 *J*=8.9, 2.8 Hz), 6.82 (1H, d, *J*=8.9 Hz), and 5.14 (2H, s).

PREPARATION 14

(5*R*,6*S*)-3-(2-Benzoyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*- butoxycarbonyl)aza-spiro[4.5]dec-3-ene

20 (5*R*,6*S*)-3-Trimethylstannyl-6-phenyl-1-oxa-7-(*tert*-
butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 6; 6.43mmol), lithium
chloride (0.163g), benzoyloxy-5-(trifluoromethoxy)phenol (Preparation 9;
7.7mmol) in toluene (25ml) was degassed before addition of
triphenylphosphine palladium (0) (0.37g). The solution was degassed
25 thoroughly before heating to 110°C for 14 hours. The solution was
partitioned between water and ethyl acetate and the dried organic phase
was purified by chromatography on a column containing silica gel (eluting
with hexane containing increasing proportions of ethyl acetate between 0%
to 4%) to give the title compound. ¹H NMR (360MHz, CDCl₃) δ 1.33 (9H,
30 s), 1.65 (1H, m), 1.76 (2H, m), 2.08 (1H, m), 3.11 (1H, m), 4.08 (1H, m),
4.60 (1H, dd, *J*=12.2 Hz, *J*=2 Hz), 4.92 (1H, dd, *J*=12.1 Hz, *J*=1.8 Hz), 5.08

(1H, s), 5.1 (2H, q, $J=11.5$ Hz), 6.65 (1H, s), 6.94 (2H, d, $J=8.9$ Hz), 7.08 (1H, d, $J=9$ Hz), 7.18 (2H, t, $J=8.1$ Hz), 7.25 (3H, m), 7.38 (5H, m).

PREPARATION 15

- 5 (3*S*,5*R*,6*S*)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane
- (5*R*,6*S*)-3-(2-Benzoyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 14) (3.88g) was dissolved in ethyl acetate (15ml) and methanol (15ml). Palladium
- 10 hydroxide on carbon (1.00g) was added and the suspension was shaken under a hydrogen atmosphere (50 psi) for 72 hours. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was purified by medium pressure chromatography on silica gel, eluting with hexane/ethyl acetate (75:25) to give (3*R*,5*R*,6*S*)-3-(2-hydroxy-
- 15 5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (191mg), ^1H NMR (250MHz, CDCl_3) δ 7.70 (2H, d, $J=7.3$ Hz), 7.33 (2H, t, $J=7.3$ Hz), 7.26 (1H, d, $J=7.3$ Hz), 7.05 (1H, br s), 6.96 (2H, m), 6.82 (1H, d, $J=9.4$ Hz), 5.43 (1H, s), 4.27 (1H, m), 4.01 (1H, m), 3.95 (1H, m), 3.73 (1H, m), 2.73 (2H, m), 2.33 (1H, m), 1.87-1.58 (4H, m);
- 20 and 1.50 (9H, s).and (3*S*,5*R*,6*S*)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (2.3g), ^1H NMR (360MHz, CDCl_3) δ 1.38 (9H, s), 1.73 (2H, m), 1.81 (1H, m), 2.18 (2H, m), 2.50 (1H, m), 2.81 (1H, m), 3.62 (1H, t, $J=7.2$ Hz), 3.92 (1H, m), 3.98 (1H, d, $J=13.2$ Hz), 4.23 (1H, m), 5.33 (1H, s), 6.75 (1H, d, $J=8.5$ Hz), 6.94 (2H,
- 25 m), 7.25 (1H, m), 7.31 (2H, m), and 7.55 (2H, d, $J=7.8$ Hz).

PREPARATION 16

(3*R*,5*R*,6*S*)-3-(2-Benzoyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

- 30 A mixture of 2-benzoyloxy-5-(trifluoromethoxy)iodobenzene (Preparation 13, 21.8g, 55.2mmol), (5*R*,6*S*)-6-phenyl-1-oxa-7-(*tert*-

butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 11, 7.0g, 22.1mmol), tetra-n-butylammonium chloride (6.18g, 22.2mmol), lithium chloride (9.35g, 0.22mol) and potassium formate (5.64g, 67.0mmol) in dimethylformamide (100ml) was degassed with a firestone valve (5 x).

5 Palladium acetate (491mg, 2.2mmol) was added and the mixture was degassed with a firestone valve (5 x). The mixture was stirred at 60°C for 15 hours, then further 2-benzyloxy-5-(trifluoromethoxy)iodobenzene (Preparation 13, 4.32g, 11.0mmol), potassium formate (2.78g, 33.5mmol) and palladium acetate (260mg, 1.1mmol) were added. The mixture was

10 stirred at 60°C for 22 hours, cooled and filtered. The solvent was evaporated under reduced pressure, water (600ml) was added and the mixture was extracted with ethyl acetate (2x300ml). The combined organic fractions were washed with brine (300ml), dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified

15 by flash column chromatography on silica gel, eluting with hexane/dichloromethane (75:25 increasing to 0:100) then dichloromethane/ethyl acetate (95:5), to give the title compound (9.42g, 73%). ¹H NMR (360MHz, CDCl₃) δ 7.56 (2H, d, *J*=7.7 Hz), 7.40-7.20 (8H, m), 7.14 (1H, d, *J*=2.0 Hz), 7.00 (1H, dd, *J*=8.9, 2.0 Hz), 6.88 (1H, d, *J*=8.9

20 Hz), 5.30 (1H, s), 5.08 (2H, s), 4.27 (1H, m), 3.97 (1H, m), 3.87 (2H, m), 2.78 (1H, m), 2.56 (1H, m), 2.15 (1H, m), 1.96 (1H, m), 1.67 (3H, m), and 1.42 (9H, s).

PREPARATION 17

25 (3*R*,5*R*,6*S*)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

Palladium on carbon (10%, 0.59g) was added to a solution of (3*R*,5*R*,6*S*)-3-(2-benzyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 16, 6.10g,

30 10.5mmol) in methanol-water (99:1, 200ml) and the mixture was stirred under hydrogen (50 psi.) for 72 hours. The mixture was filtered, washing

with ethanol, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with dichloromethane/ethyl acetate (99:1 increasing to 90:10) to give the title compound. ¹H NMR (360MHz, CDCl₃) δ 7.70 (2H, d, *J*=7.3 Hz), 7.33 (2H, t, *J*=7.3 Hz), 7.26 (1H, d, *J*=7.3 Hz), 7.05 (1H, br s), 6.96 (2H, m), 6.82 (1H, d, *J*=9.4 Hz), 5.43 (1H, s), 4.27 (1H, m), 4.01 (1H, m), 3.95 (1H, m), 3.73 (1H, m), 2.73 (2H, m), 2.33 (1H, m), 1.87-1.58 (4H, m), and 1.50 (9H, s).

PREPARATION 18

(3*S*,5*R*,6*S*)-3-[2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

(3*S*,5*R*,6*S*)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 15) (290mg, 0.59mmol) was dissolved in toluene (5ml) and silver carbonate (179mg, 0.65mmol) was added in one portion. (1-Iodocycloprop-1-yl)phenylsulfide (Cohen T. and Matz J. R., *J. Am. Chem. Soc.* 1980, 102, 6902) (180mg, 0.65mmol) was then added over one minute at room temperature. The mixture was stirred at 55°C for 4 hours, then further portions of silver carbonate (179mg, 0.65mmol) and (1-iodocycloprop-1-yl)phenylsulfide (180mg, 0.65mmol) were added. The mixture was stirred at 55°C for a further 3 hours, cooled, filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 80:20) to give the title compound as a colourless oil (120mg, 32%). ¹H NMR (250MHz, CDCl₃) δ 7.55-7.44 (4H, m), 7.36-7.23 (7H, m), 7.13-7.02 (2H, m), 5.16 (1H, br s), 4.09 (1H, t, *J*=6 Hz), 4.03-3.92 (1H, m), 3.67-3.49 (2H, m), 2.94-2.79 (1H, m), 2.26 (1H, dd, *J*=7.9, 12.9 Hz), 2.15-2.01 (2H, m), 1.76-1.59 (3H, m), 1.53-1.45 (4H, m), and 1.36 (9H, s). *m/z* (ES⁺) 642 (M+1).

PREPARATION 19

(3*R*,5*R*,6*S*)-3-[2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

- 5 Prepared from (3*R*,5*R*,6*S*)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 17) according to the method of Preparation 18. ¹H NMR (360MHz, CDCl₃) δ 7.57 (2H, app. d, *J*=7.6 Hz), 7.45 (2H, app. d, *J*=7.7 Hz), 7.36-7.19 (7H, m), 7.16-7.06 (2H, m), 5.28 (1H, br s),
10 4.13 (1H, app. t, *J*=7.8 Hz), 3.96 (1H, br. d, *J*=13 Hz), 3.80-3.60 (2H, m), 2.79 (1H, br. t, *J*=13 Hz), 2.50 (1H, dd, *J*=13, 7.9 Hz), 2.17 (1H, dt, *J*=13, 4.6 Hz), 1.80 (1H, dd, *J*=12, 9.8 Hz), 1.75-1.38 (7H, m), and 1.44 (9H, s).
m/z (ES⁺) 642 (M+1).

15 PREPARATION 20

(3*S*,5*R*,6*S*)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

- Naphthalene (120mg, 0.936mmol) was dissolved in THF (1.5ml) under nitrogen and freshly cut lithium metal (7.0mg, 0.94mmol) was
20 added. The mixture was then sonicated at room temperature for 20 minutes to produce a dark green solution of lithium naphthalenide. This solution was cooled to -78.°C, then (3*S*,5*R*,6*S*)-3-[2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-
butoxycarbonyl)aza-spiro[4.5]decane (Preparation 18) (120mg, 0.187mmol)
25 in THF (0.5ml) was added over 1 minute. The reaction mixture was stirred for 30 minutes, then water (5ml) and ether (10ml) were added. The layers were separated and the aqueous layer was extracted with ether (10ml). The combined organic fractions were dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified
30 by column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 80:20) to give the title compound as a colourless oil

(58.6mg, 59%). ^1H NMR (250MHz, CDCl_3) δ 7.58-7.52 (2H, m), 7.36-7.17 (4H, m), 7.10-7.01 (2H, m), 5.18 (1H, br s), 4.20 (1H, t, $J=6.7$ Hz), 4.05-3.95 (1H, m), 3.76-3.55 (3H, m), 2.92-2.79 (1H, m), 2.37 (1H, dd, $J=12.9$, 7.8 Hz), 2.18-2.06 (2H, m), 1.80-1.67 (3H, m), 1.38 (9H, s), and 0.86-0.73 (4H, m). m/z (ES^+) 534 ($M+1$).

PREPARATION 21

(3*R*,5*R*,6*S*)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane

10 Naphthalene (120mg, 0.936mmol) was dissolved in THF (1.5ml) under nitrogen and freshly cut lithium metal (7.0mg, 0.94mmol) was added. The mixture was then sonicated at room temperature for 20 minutes to produce a dark green solution of lithium naphthalenide. A solution of (3*R*,5*R*,6*S*)-3-[2-(1-phenylthiocycloprop-1-yl)oxy-5-

15 (trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 19, 135mg, 0.21mmol) in THF (2ml) under nitrogen was cooled to -78°C and the solution of lithium naphthalenide in THF was added dropwise until the intense green colour persisted. The reaction was then stirred for one minute, water (5ml) was added and the

20 mixture was warmed to room temperature. Ether (10ml) was added and the layers were separated. The aqueous phase was extracted with a further portion of ether (10ml) and the combined organic phases were dried (MgSO_4) and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting

25 with hexane/ethyl acetate (50:50) to give the title compound as a colourless oil (87mg, 78%). ^1H NMR (360MHz, CDCl_3) δ 7.59 (2H, app. d, $J=7.6$ Hz), 7.32 (2H, app. t, $J=7.6$ Hz), 7.27-7.18 (2H, m), 7.11-7.03 (2H, m), 5.32 (1H, br s), 4.29-4.21 (1H, m), 3.97 (1H, br. d, $J=13$ Hz), 3.83-3.68 (3H, m), 2.76 (1H, dt, $J=13$, 4.1 Hz), 2.55 (1H, dd, $J=13$, 7.2 Hz), 2.22 (1H, dt, $J=12$, 5.2

30 Hz), 1.85 (1H, dd, $J=13$, 9.9 Hz), 1.80-1.63 (3H, m), 1.46 (9H, s), and 0.82-0.76 (4H, m). m/z (ES^+) 534 ($M+1$).

COMPOUND A

(3S,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane Hydrochloride

- 5 Trifluoroacetic acid (2.5ml) was added dropwise to a stirred, cooled (0°C) solution of (3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(*tert*-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 20; 492mg, 0.92mmol) in dichloromethane (25ml) and the mixture was stirred at room temperature for 3 hours. The mixture was poured into
- 10 water (50ml), the pH was adjusted to 10.0 with aqueous sodium hydroxide (4M) and the mixture was extracted with dichloromethane (3x50ml). The combined organic fractions were dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with
- 15 dichloromethane/methanol/ammonia (aq.) (96:4:0.4 increasing to 94:6:0.6). The residue was dissolved in ethanol (20ml), cooled in ice and ethereal hydrogen chloride (1M, 1.8ml, 1.8mmol) was added dropwise. The mixture was stirred at 0°C for 5 minutes, then the solvent was evaporated under reduced pressure. The residue was crystallized from ether (20ml)/ethanol
- 20 (0.5ml) and the solid was collected and dried *in vacuo* to give the title compound as a colorless solid (354mg, 89%). m.p. 214-216 °C, ¹H NMR (500MHz, CD₃OD) δ 7.59 (2H, m), 7.52 (3H, m), 7.26 (1H, d, *J*=8.9 Hz), 7.03 (1H, dd, *J*=8.9, 2.2 Hz), 6.20 (1H, d, *J*=2.2 Hz), 4.85 (2H, br s), 4.43 (1H, s), 4.19 (1H, t, *J*=8.0 Hz), 3.87 (1H, quin, *J*=8.0 Hz), 3.76 (1H, m),
- 25 3.44 (1H, m), 3.25 (2H, m) 2.29-1.78 (6H, m), 0.80 (2H, m), and 0.66 (2H, m). m/z (ES⁺) 434 (M+1). Found: C, 61.41; H, 5.51; N, 3.08. C₂₄H₂₆F₃NO₃.HCl requires: C, 61.34; H, 5.79; N, 2.98%.

COMPOUND B

(3R,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane

Prepared from the compound of Preparation 21 according to the method used for Compound A. ¹H NMR (360MHz, CDCl₃) δ 7.50-7.42 (2H, m), 7.36-7.26 (3H, m), 7.03 (1H, d, *J*=8.9 Hz), 6.95 (1H, br. d, *J*=8.9 Hz), 6.81 (1H, br s), 3.92 (1H, t, *J*=7.4 Hz), 3.62-3.53 (2H, m), 3.50 (1H, s), 3.20 (1H, dd, *J*=12, 4.2 Hz), 2.77 (1H, dt, *J*=12, 2.8 Hz), 2.30-1.93 (4H, m), 1.87 (1H, br s), 1.71-1.49 (3H, m), 0.76-0.65 (2H, m), and 0.65-0.54 (2H, m). *m/z* (ES⁺) 434 (M+1).

A further compound and diastereomers thereof of use in the present invention may be prepared according to the following method:

DESCRIPTION 1

2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzaldehyde

Silver carbonate (1.2 g, 4.34 mmol) was added to a solution of 2-hydroxy-5-(trifluoromethoxy)benzaldehyde (0.5 g, 2.43 mmol) and (1-iodocycloprop-1-yl)phenylsulfide (Cohen T. and Matz J. R., *J. Am. Chem. Soc.* **1980**, *102*, 6902) (1.2 g, 4.34 mmol) in toluene (30 mL) and the mixture was stirred at 40 °C overnight. The mixture was cooled, diluted with ethyl acetate and filtered, washing well with ethyl acetate. The mixture was washed with aqueous sodium hydroxide, dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (95:5), to give the title compound as a yellow oil (191 mg, 27%). ¹H NMR (360MHz, CDCl₃) δ 1.51-1.56 (2H, m), 1.44-1.48 (2H, m), 7.25-7.35 (7H, m), 7.69 (1H, d, *J* 2.0 Hz), and 10.26 (1H, s).

DESCRIPTION 2

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde

Freshly cut lithium metal (97 mg, 13.9 mmol) was added to a solution of naphthalene (1.77 g, 13.9 mmol) in THF (20 mL) and the mixture was sonicated at room temperature for 30 min. to produce a dark green solution of lithium naphthalenide. A solution of 2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzaldehyde (Description 1, 96 mg, 0.27 mmol) in THF (2 mL) was cooled to -78 °C and the solution of lithium naphthalenide in THF (2 mL) was added dropwise until the intense green colour persisted. The reaction was then stirred for 5 min., water (6 mL) was added and the mixture was warmed to room temperature. The mixture was extracted with ethyl acetate, the combined organic fractions were dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (80:20), to give the title compound as a colourless oil (4 mg, 6%). ¹H NMR (360MHz, CDCl₃) δ 0.86 (4H, m), 3.82-3.9 (1H, m), 7.42 (2H, m), 7.62 (1H, d, *J* 2.5 Hz), and 10.36 (1H, s).

DESCRIPTION 3

2-Nitro-4-(trifluoromethoxy)phenol

Iron(III)nitrate nonahydrate (1.97 g, 4.87 mmol) was added to a solution of 4-(trifluoromethoxy)phenol (2 g, 11.24 mmol) in ethanol (20 mL) and the mixture was heated under reflux overnight. The mixture was allowed to cool to room temperature, acidified to pH 1 with aqueous hydrochloric acid (1M) and extracted with ethyl acetate. The combined organic fractions were dried (MgSO₄), and the solvent was evaporated under reduced pressure. The residue was purified by short column chromatography on silica gel, eluting with hexane/EtOAc (70:30), to give the title compound as a yellow oil (2.25 g, 89%). ¹H NMR (360MHz, CDCl₃)

δ 10.53 (1H, s), 8.01 (1H, d, J 3.0 Hz), 7.49 (1H, dd, J 9.1, 3.0 Hz), and 7.23 (1H, d, J 9.1 Hz).

DESCRIPTION 4

5 2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)nitrobenzene

Prepared from the compound of Description 3 according to the method of Description 1. ^1H NMR (360MHz, CDCl_3) δ 7.73 (1H, d, J 2.7 Hz), 7.58 (1H, d, J 9.2 Hz), 7.50-7.24 (6H, m), 1.57-1.53 (2H, m), and 1.44-1.40 (2H, m).

10

DESCRIPTION 5

2-Cyclopropoxy-5-(trifluoromethoxy)benzeneamine

Prepared from the compound of Description 4 according to the method of Description 2. ^1H NMR (360MHz, CDCl_3) δ 7.06 (1H, dd, J 2.8, 6.7 Hz), 6.56 (2H, m), 3.83 (2H, br s), 3.74 (1H, m), and 0.79 (4H, m). m/z (ES $^+$) 234 (M+1).

15

DESCRIPTION 6

2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzeneamine

20 Iron powder (13.5 g, 241 mmol) was added to a suspension of 2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)nitrobenzene (Description 4, 11.27 g, 30.1 mmol) in water (300 mL) and acetic acid (75 mL) and the mixture was stirred at 80 °C overnight. The mixture was cooled and filtered through celite, washing with ether. The filtrate was
25 extracted with ether, the combined organic fractions were washed with aqueous sodium hydroxide (1M), dried (MgSO_4), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/ Et_2O (90:10 increasing to 80:20), to give the title compound as a yellow solid (8 g, 78%).
30 ^1H NMR (360MHz, CDCl_3) δ 7.48 (2H, m), 7.34-7.23 (3H, m), 7.15 (1H, d, J

8.74 Hz), 6.60-6.56 (2H, m), 3.78 (2H, br s), 1.49-1.46 (2H, m), and 1.39-1.35 (2H, m).

DESCRIPTION 7

5 2-Cyclopropoxy-5-(trifluoromethoxy)benzeneamine

Prepared from the compound of Description 6 according to the method of Description 2. ¹H NMR (360MHz, CDCl₃) δ 7.06 (1H, dd, *J* 2.8, 6.7 Hz), 6.56 (2H, m), 3.83 (2H, br s), 3.74 (1H, m), and 0.79 (4H, m). *m/z* (ES⁺) 234 (M+1).

10

DESCRIPTION 8

2-Cyclopropoxy-5-(trifluoromethoxy)iodobenzene

An ice-cooled solution of sodium nitrite (3.55 g, 51 mmol) in water (10 mL) was added dropwise to a stirred, cooled (0 °C) solution of

15 2-cyclopropoxy-5-(trifluoromethoxy)benzeneamine (Description 7, 4.8 g, 20.6 mmol) in aqueous hydrochloric acid (5M, 300 mL), maintaining the internal temperature at 0 °C. The mixture was stirred at 0 °C for 30 min., then potassium iodide (8.55 g, 51.5 mmol) in water (10 mL) was added dropwise, maintaining the internal temperature at 0 °C. The mixture was

20 stirred at 0 °C for 30 min., then allowed to warm up to room temperature and stirred until nitrogen evolution ceased. The mixture was extracted with ether, the organic fraction was washed with aqueous sodium thiosulfate (10%), dried (MgSO₄), and the solvent was evaporated under reduced pressure. The residue was purified by flash column

25 chromatography on silica gel, eluting with hexane/Et₂O (98:2 increasing to 95:5), to give the title compound as a colourless oil (6.23 g, 88%). ¹H NMR (360MHz, CDCl₃) δ 7.62 (1H, d, *J* 2.4 Hz), 7.20 (1H, dd, *J* 9.1, 2.4 Hz), 7.15 (1H, d, *J* 9.1 Hz), 3.80 (1H, m), and 0.83 (4H, m).

DESCRIPTION 9

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde

A solution of 2-cyclopropoxy-5-(trifluoromethoxy)iodobenzene (Description 8, 0.344 g, 1 mmol) in toluene (2.5 mL) was degassed with
5 bubbling nitrogen for 10 min. Tetrakis(triphenylphosphine)palladium (0) (15 mg) was added, the mixture was degassed with bubbling nitrogen for a further 5 min., then carbon monoxide was bubbled through the mixture for 10 min. The mixture was warmed to 50 °C and a solution of tributyl tin hydride (0.3 mL, 1.1 mmol) in toluene (5 mL) was added at a rate of 2
10 mL/h. *via* a syringe pump, maintaining carbon monoxide bubbling throughout. The mixture was cooled, diluted with ether (20 mL) and aqueous potassium fluoride solution (50%) was added. The mixture was stirred at room temperature overnight, filtered and the layers were separated. The organic layer was dried (MgSO₄), and the solvent was
15 evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (80:20), to give the title compound as a colourless oil. ¹H NMR (360MHz, CDCl₃) δ 0.86 (4H, m), 3.82-3.9 (1H, m), 7.42 (2H, m), 7.62 (1H, d, *J* 2.5 Hz), and 10.36 (1H, s).

20

DESCRIPTION 10

(±)-(2*RS*)-1-*tert*-Butoxycarbonyl-2-phenylpiperidin-3-one

Dimethyl sulfoxide (32.0 mL, 35.3 g, 0.45 mol) in dichloromethane (100 mL) was added dropwise to a cooled (-70 °C) solution of oxalyl
25 chloride (18.7 mL, 27.5 g, 0.22 mol) in dichloromethane (1000 mL). The mixture was stirred at -70 °C for 15 min., then (2*S*,3*S*)-1-*tert*-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared by the method described in European Patent Specification number 0 528 495-A; 50 g, 0.18 mol) in dichloromethane (150 mL) was added dropwise.
30 The mixture was stirred at -70 °C for 1 h., then triethylamine (125.8 mL, 91.3 g, 0.9 mol) was added slowly. The mixture was stirred at room

temperature for 1 h., water (250 mL) and aqueous sodium hydrogen carbonate (saturated, 250 mL) were added and the mixture was stirred at room temperature overnight. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 300 mL). The combined
5 organic fractions were washed with brine, dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/EtOAc (90:10), to give the title compound as a yellow oil (45.0 g, 91%). ¹H NMR (250MHz, CDCl₃) δ 7.5-7.3 (5H, m), 5.8 (1H, br s), 4.2 (1H, br s), 3.4 (1H, m), 2.6 (2H,
10 m), 2.0 (2H, m), and 1.54 (9H, s).

DESCRIPTION 11

(±)-(2R3R,2S3S)-1-(tert-Butoxycarbonyl)-2-phenylpiperidin-3-amine

A solution of hydroxylamine hydrochloride (17 g, 0.24 mol) and
15 sodium acetate (55.67 g, 0.41 mol) in water (150 mL) was added to a solution of (±)-(2RS)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one (Description 10, 45 g, 0.16 mol) in ethanol (300 mL) and the mixture was stirred at room temperature for 1 h. The solvent was evaporated under reduced pressure, water was added and the mixture was extracted with
20 ethyl acetate. The organic fraction was washed with brine, dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanol (400 mL) and Raney nickel (50 g) was added. The mixture was shaken under hydrogen (40 psi) overnight, filtered and the solvent was evaporated under reduced pressure. The residue was purified
25 by flash column chromatography on silica gel, eluting with CH₂Cl₂/MeOH (100:0 increasing to 85:15), to give the title compound as a colorless oil (10.9 g, 24%). ¹H NMR (360MHz, CDCl₃) δ 7.43 (2H, d, *J* 7.0 Hz), 7.30 (3H, m), 5.19 (1H, d, *J* 6.2 Hz), 4.00 (1H, m), 3.17 (2H, m), 1.90-1.64 (4H, m), 1.36 (9H, s), and 1.26 (2H, br s).

COMPOUND C

(±)-(2R3R,2S3S)-N-{[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]methyl}-2-phenylpiperidin-3-amine Dihydrochloride

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde (Description 9, 55
5 mg, 0.21 mmol) was added to (±)-(2R3R,2S3S)-1-(*tert*-butoxycarbonyl)-2-phenylpiperidin-3-amine (Description 11, 58 mg, 0.21 mmol), citric acid (89 mg, 0.42 mmol) and 3Å molecular sieves in dry methanol (5 mL) and the mixture was stirred at room temperature for 1.5 h. Sodium borohydride (30 mg) was added and the mixture was stirred at room
10 temperature for 2 h. Ethyl acetate was added and the mixture was washed with aqueous hydrochloric acid (0.1M, 2 x 25 mL) and brine (25 mL), dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane (3 mL), cooled to 0 °C and trifluoroacetic acid (2 mL) was added slowly. The mixture was stirred at
15 room temperature for 1 h., the solvent was evaporated under reduced pressure and ethyl acetate was added. The mixture was washed with aqueous sodium hydrogen carbonate (saturated, 2 x 25 mL) and brine (25 mL), dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on
20 silica gel, eluting with CH₂Cl₂/MeOH/NH₃(Aq.) (96:4:0.4). The residue was dissolved in ethanol (2 mL), cooled in ice and ethereal hydrogen chloride (1M, 0.24 mL, 0.24 mmol) was added. The solvent was evaporated under reduced pressure and the residue was recrystallised from ethanol to give the title compound as a colorless solid (20 mg, 20%). m.p. 169-171 °C. ¹H
25 NMR (400MHz, CD₃OD) δ 0.64 (1H, m), 0.80 (3H, m), 1.99 (1H, m), 2.24 (1H, m), 2.46 (2H, m), 3.30 (1H, m), 3.64 (1H, m), 3.75 (2H, m), 3.96 (1H, br s), 4.08 (1H, m), 4.95 (1H, s), 7.23 (1H, s), 7.31 (1H, d, *J* 9.0 Hz), 7.37 (1H, d, *J* 9.0 Hz), 7.54 (3H, m), and 7.67 (2H, m). m/z (ES⁺) 407 (M+1).

30 Particularly preferred NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor

antagonists, i.e. compounds with an NK-1 receptor affinity (IC_{50}) of less than 10nM, favourably less than 2nM and preferably less than 1nM.

The class of orally active, long acting, CNS-penetrant NK-1 receptor antagonists of use in the present invention is identified using a
5 combination of the following assays:

ASSAY 1: NK-1 Receptor binding

NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a
10 modification of the assay conditions described by Cascieri *et al*, *J. Pharmacol. Exp. Ther.*, 1992, 42, 458. Typically, the receptor is expressed at a level of 3×10^5 receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay. ^{125}I -Tyr⁸-
15 substance P (0.1nM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 5 μ l dimethylsulphoxide, DMSO) with 5×10^4 CHO cells. Ligand binding is performed in 0.25ml of 50mM Tris-HCl, pH7.5, containing 5mM $MnCl_2$, 150mM NaCl, 0.02% bovine serum albumin (Sigma), 50 μ g/ml chymostatin
20 (Peninsula), 0.1nM phenylmethylsulphonyl fluoride, 2 μ g/ml pepstatin, 2 μ g/ml leupeptin and 2.8 μ g/ml furoyl saccharine. The incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters pre-soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Non-
25 specific binding is determined using excess substance P (1 μ M) and represents <10% of total binding.

ASSAY 2: Gerbil Foot-Tapping

CNS-penetrant NK-1 receptor antagonists for use in the present
30 invention can be identified by their ability to inhibit foot tapping in gerbils induced by anxiogenic agents (such as pentagastrin) or central infusion of

NK-1 receptor agonists such as GR73632, or caused by aversive stimulation such as foot shock or single housing, based on the method of Rupniak & Williams, *Eur. J. Pharmacol.*, 1994, 265, 179.

Male or female Mongolian gerbils (35-70g) are anaesthetised by
5 inhalation of an isoflurane/oxygen mixture to permit exposure of the
jugular vein in order to permit administration of test compounds or vehicle
in an injection volume of 5ml/kg i.v. Alternatively, test compounds may be
administered orally or by subcutaneous or intraperitoneal routes. A skin
incision is then made in the midline of the scalp to expose the skull. An
10 anxiogenic agent (e.g. pentagastrin) or a selective NK-1 receptor agonist
(e.g. GR73632 (d Ala[L-Pro⁹,Me-Leu¹⁰]-substance P-(7-11)) is infused
directly into the cerebral ventricles (e.g. 3pmol in 5µl i.c.v., depending on
test substance) by vertical insertion of a cuffed 27 gauge needle to a depth
of 4.5mm below bregma. The scalp incision is closed and the animal
15 allowed to recover from anaesthesia in a clear perspex observation box
(25cm x 20cm x 20cm). The duration and/or intensity of hind foot tapping
is then recorded continuously for approximately 5 minutes. Alternatively,
the ability of test compounds to inhibit foot tapping evoked by aversive
stimulation, such as foot shock or single housing, may be studied using a
20 similar method of quantification.

ASSAY 3: Ferret Emesis

Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by
gavage with test compound. Ten minutes later they are fed with
25 approximately 100g of tinned cat food. At 60 minutes following oral
dosing, cisplatin (10mg/kg) is given i.v. *via* a jugular vein catheter
inserted under a brief period of halothane anaesthesia. The catheter is
then removed, the jugular vein ligated and the skin incision closed. The
ferrets recover rapidly from the anaesthetic and are mobile within 10-20
30 minutes. The animals are observed continuously during recovery from the
anaesthetic and for 4 hours following the cisplatin injection, after which

time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administration are recorded by trained observers.

5 ASSAY 4: Separation-Induced Vocalisation

Male and female guinea-pigs pups are housed in family groups with their mothers and littermates throughout the study. Experiments are commenced after weaning when the pups are 2 weeks old. Before entering an experiment, the pups are screened to ensure that a vigorous
10 vocalisation response is reproducibly elicited following maternal separation. The pups are placed individually in an observation cage (55cm x 39cm x 19cm) in a room physically isolated from the home cage for 15 minutes and the duration of vocalisation during this baseline period is recorded. Only animals which vocalise for longer than 5 minutes are
15 employed for drug challenge studies (approximately 50% of available pups may fail to reach this criterion). On test days each pup receives an oral dose or an s.c. or i.p. injection of test compound or vehicle and is then immediately returned to the home cage with its mother and siblings for 30 to 60 minutes (or for up to 4 hours following an oral dose, dependent upon
20 the oral pharmacokinetics of the test compound) before social isolation for 15 minutes as described above. The duration of vocalisation on drug treatment days is expressed as a percentage of the pre-treatment baseline value for each animal. The same subjects are retested once weekly for up to 6 weeks. Between 6 and 8 animals receive each test compound at each
25 dose tested.

As used herein, the term "CNS-penetrant" refers to NK-1 receptor antagonists which are able to inhibit NK-1 receptor antagonist-induced foot-tapping in the gerbil as hereinafter defined.

Essentially, hind foot-tapping in the gerbil induced by infusion of
30 the NK-1 receptor agonist, GR73632 (d Ala[L-Pro⁹,Me-Leu¹⁰]-substance P-(7-11)), under anaesthesia, directly into the central ventricles is inhibited

when a CNS-penetrant NK-1 receptor antagonist is administered intravenously immediately prior to GR73632 challenge, wherein hind foot-tapping over a period of five minutes following recovery from the anaesthesia is inhibited with an $ID_{50} \leq 3 \text{ mg/kg}$, and preferably with an

5 $ID_{50} \leq 1 \text{ mg/kg}$.

In an alternative method, the NK-1 receptor antagonist is administered orally, 1 hour prior to GR73632 challenge, wherein the foot-tapping over a period of five minutes following recovery from anaesthesia is inhibited with an $ID_{50} \leq 30 \text{ mg/kg}$, and preferably with an $ID_{50} \leq 10 \text{ mg/kg}$.

10 CNS-penetrant NK-1 receptor antagonists of use in the present invention are also effective in the attenuation of separation-induced vocalisations by guinea-pig pups as hereinafter defined.

Essentially, a vocalisation response in guinea-pig pups is induced by isolation from their mothers and littermates, which response is attenuated

15 when a CNS-penetrant NK-1 receptor antagonist is administered subcutaneously 30 minutes prior to isolation, wherein vocalisations during the first 15 minutes of isolation are attenuated with an $ID_{50} \leq 20 \text{ mg/kg}$, preferably with an $ID_{50} \leq 10 \text{ mg/kg}$, and especially with an $ID_{50} \leq 5 \text{ mg/kg}$.

In an alternative method, the NK-1 receptor antagonist is

20 administered orally, 4 hours prior to isolation, wherein vocalisations during the first 15 minutes of isolation are attenuated with an $ID_{50} \leq 20 \text{ mg/kg}$, preferably with an $ID_{50} \leq 10 \text{ mg/kg}$, and especially with an $ID_{50} \leq 5 \text{ mg/kg}$.

A suitable selection cascade for NK_1 antagonists of use according to

25 the present invention is as follows:

(i) Determine affinity for human NK_1 receptor in radioligand binding studies (Assay 1); select compounds with $IC_{50} \leq 10 \text{ nM}$, preferably $IC_{50} \leq 2 \text{ nM}$, especially $IC_{50} \leq 1 \text{ nM}$.

(ii) Determine ability of compounds to penetrate CNS by their

30 ability to inhibit foot tapping in gerbils induced by central injection of an NK_1 agonist (Assay 2); select compounds that inhibit foot tapping with

$ID_{50} \leq 3\text{mg/kg i.v.}$, and preferably $ID_{50} \leq 1\text{mg/kg i.v.}$ when administered immediately prior to central NK_1 agonist challenge, or $ID_{50} \leq 30\text{mg/kg p.o.}$, and preferably $ID_{50} \leq 10\text{mg/kg p.o.}$ 1 hour prior to challenge.

(iii) Determine central duration of action of compounds in gerbil foot tapping assay following intravenous administration 24 hours prior to central NK_1 agonist challenge; select compounds showing ≤ 25 -fold loss of potency compared with ID_{50} determined in step (ii) above with the proviso that $ID_{50} \leq 10\text{mg/kg i.v.}$, and preferably $\leq 5\text{mg/kg i.v.}$ after 24 hour pre-treatment.

(iv) Determine oral bioavailability of compounds by pharmacokinetic analysis, activity in gerbil foot tapping assay following oral administration and/or by ability to inhibit cisplatin-induced emesis in ferrets (Assay 3); select compounds with $ID_{90} \leq 3\text{mg/kg p.o.}$, and preferably $ID_{90} \leq 1\text{mg/kg p.o.}$

Particularly preferred compounds of use in the present invention are identified using steps (i) to (iv) followed by step (v):

(v) Determine activity of compounds in assays sensitive to conventional antipsychotic drugs (inhibition of distress vocalisations in guinea-pig pups (Assay 4)). Select compounds with $ID_{50} \leq 20\text{mg/kg}$, and preferably $ID_{50} \leq 10\text{mg/kg}$.

Yet further preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK_1 receptor binding criteria of step (i) which, in addition, have ≤ 5 -fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.

One example of a NK_1 receptor antagonist of use in the present invention is the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity:

human NK-1 receptor binding: $IC_{50}=0.1nM$
gerbil foot-tapping (5 mins.): $ID_{50}=0.36mg/kg$ i.v.
gerbil foot-tapping (24 hrs.): $ID_{50}=0.33mg/kg$ i.v.
ferret emesis: $ID_{90}<3mg/kg$ p.o.
guinea-pig vocalisation
(4 hr. pre-treatment): $ID_{50}=0.73mg/kg$ p.o.

The following example illustrates pharmaceutical compositions according to the invention.

EXAMPLE 1 Tablets containing 50-300mg of NK-1 antagonist

	<u>Amount mg</u>		
NK-1 antagonist	50.0	100.0	300.0
Microcrystalline cellulose	80.0	80.0	80.0
Modified food corn starch	80.0	80.0	80.0
Lactose	189.5	139.5	139.5
Magnesium Stearate	0.5	0.5	0.5

- 5 The active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 50mg, 100mg and 300mg of the
- 10 NK-1 receptor antagonist per tablet.

- Pharmaceutical compositions comprising a combination of a NK-1 receptor antagonist and a neuroleptic agent may be prepared with separate active ingredients or with a combination of active ingredients in one composition. In such combined preparations, the ratio of the NK-1
- 15 receptor antagonist and the neuroleptic agent will depend upon the choice of active ingredients.

EXAMPLE 2 Tablets containing 50-300mg of NK-1 antagonist and 5-10mg of haloperidol

	<u>Amount mg</u>					
NK-1 antagonist	50.0	50.0	100.0	100.0	300.0	300.0
haloperidol	5.0	10.0	5.0	10.0	5.0	10.0
Microcrystalline cellulose	80.0	80.0	80.0	80.0	80.0	80.0
Modified food corn starch	80.0	80.0	80.0	80.0	80.0	80.0
Lactose	184.5	179.5	134.5	129.5	134.5	129.5
Magnesium Stearate	0.5	0.5	0.5	0.5	0.5	0.5

5 The active ingredients, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 50mg, 100mg and 300mg of the CNS-penetrant NK-1 receptor antagonist per tablet.

CLAIMS

1. Use of an orally active, long acting, CNS-penetrant NK-1
5 receptor antagonist for the manufacture of a medicament for oral
administration for the treatment or prevention of movement disorders.
2. Use of an orally active, long acting, CNS-penetrant NK-1
receptor antagonist for the manufacture of a medicament for oral
10 administration for the treatment or prevention dyskinesias in a patient
who is non-responsive to neuroleptic agents, or for whom neuroleptic
agents are contraindicated.
3. Use of a NK-1 receptor antagonist and an antiparkinsonian
15 agent for simultaneous, separate or sequential administration for the
manufacture of a medicament for the treatment or prevention of akinetic-
rigid disorders.
4. Use of a NK-1 receptor antagonist and a neuroleptic agent for
20 simultaneous, separate or sequential administration for the manufacture
of a medicament for the treatment or prevention of dyskinesias.
5. An oral pharmaceutical composition for the treatment of
movement disorders which comprises an orally active, long acting, CNS-
25 penetrant NK-1 receptor antagonist, together with a pharmaceutically
acceptable carrier or excipient.
6. A pharmaceutical composition comprising a NK-1 receptor
antagonist and an antiparkinsonian agent, together with at least one
30 pharmaceutically acceptable carrier or excipient.

7. A pharmaceutical composition comprising a NK-1 receptor antagonist and a neuroleptic agent, together with at least one pharmaceutically acceptable carrier or excipient.
- 5 8. A product comprising a NK-1 receptor antagonist and an antiparkinsonian agent as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention of akinetic-rigid disorders.
- 10 9. A product comprising a NK-1 receptor antagonist and an antiparkinsonian agent as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention of dyskinesias.
- 15 10. A method for the treatment or prevention of movement disorders, which method comprises the oral administration to a patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
- 20 11. A method for the treatment or prevention of dyskinesias in a patient who is non-responsive to neuroleptic agents or for whom neuroleptic agents are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
- 25 12. A method for the treatment or prevention of akinetic-rigid disorders, which method comprises administration to a patient in need of such treatment of an amount of a NK-1 receptor antagonist and an amount of an antiparkinsonian agent, such that together they give
- 30 effective relief.

13. A method for the treatment or prevention of dyskinesias, which method comprises administration to a patient in need of such treatment of an amount of a NK-1 receptor antagonist and an amount of a neuroleptic agent, such that together they give effective relief.

5

14. A use according to claim 1, 2, 3 or 4, or a composition according to claim 5, 6 or 7, or a product according to claim 8 or 9 or a method according to claim 10, 11, 12 or 13 wherein the NK-1 receptor antagonist is selected from the classes of compounds described in EP-A-
10 0577394, WO-A-9508549, WO-A-9518124, WO-A-9523798, WO-A-9605181 and International Patent Application No. PCT/GB97/01630.

15. A use according to claim 1, 2, 3 or 4, or a composition according to claim 5, 6 or 7, or a product according to claim 8 or 9 or a
15 method according to claim 10, 11, 12 or 13 wherein the NK-1 receptor antagonist is:

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-1H,4H-
20 1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

25 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;

30 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;
5 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(5-oxophosphoryl-1H-1,2,4-triazolo)methyl)morpholine;
2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(1-monophosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N-
10 dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-
7-aza-spiro[4.5]decane;
(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-
7-aza-spiro[4.5]decane;
15 (±)-(2R3R,2S3S)-N-[[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]methyl]-2-
phenylpiperidin-3-amine;
or a pharmaceutically acceptable salt thereof.

16. A use according to claim 1, or a composition according to
20 claim 5 or a method according to claim 10 wherein the movement
disorders are selected from akinesias and akinetic-rigid syndromes,
dyskinesias and medication-induced parkinsonian.

17. A use according to claim 1, or a composition according to
25 claim 5 or a method according to claim 10 wherein the movement disorder
is Gilles de la Tourette syndrome, and the symptoms thereof.

18. A use according to claim 2 or 4, or a composition according to
claim 7, or a product according to claim 9, or a method according to claim
30 11 or 13 or a use, composition or method according to claim 16 wherein the

dyskinesias are selected from tremor, chorea, myoclonus, tics, and dystonia.

19. A use according to claim 3, or a composition according to
5 claim 6, or a product according to claim 8, or a method according to claim
12 or a use, composition or method according to claim 16 wherein the
akineti-rigid disorders or syndromes are selected from Parkinson's
disease, drug-induced parkinsonism, postencephalitic parkinsonism,
progressive supranuclear palsy, multiple system atrophy, corticobasal
10 degeneration, parkinsonian-ALS dementia complex and basal ganglia
calcification.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/06692

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/535 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB 2 274 777 A (RHÔNE-POULENC RORER) 10 August 1994 see page 64, line 1 - line 18; claims; examples	1-19
Y	--- WO 96 29326 A (GLAXO) 26 September 1996 see page 7, line 4 - line 8; claims; examples	1-19
A	--- WO 96 05181 A (MERCK SHARP & DOHME) 22 February 1996 cited in the application see page 16, line 16 - line 25; claims; examples --- -/--	1-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

6 April 1998

Date of mailing of the international search report

30 04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

Internati Application No
PCT/EP 97/06692

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 08549 A (GLAXO) 30 March 1995 cited in the application see page 11, line 8 - line 13; claims; examples ---	1-19
A	EP 0 577 394 A (MERCK & CO.) 5 January 1994 cited in the application see page 19, line 34 - line 39; claims; examples ---	1-19
A	WO 95 18124 A (MERCK SHARP & DOHME) 6 July 1995 cited in the application see page 3, line 12 - line 24; claims; examples -----	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 97/ 06692

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10-13
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10-13 are drawn to a method of treatment of the human or animal body by therapy (Rule 39.1(iv) PCT) the search has been carried out based on the alleged effects of the compounds and compositions.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/06692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2274777 A	10-08-94	FR 2700472 A	22-07-94
		AT 150972 T	15-04-97
		AU 682166 B	25-09-97
		AU 5862794 A	15-08-94
		BE 1006705 A	22-11-94
		CA 2152401 A	04-08-94
		CH 687503 A	31-12-96
		DE 69402411 D	07-05-97
		DE 69402411 T	30-10-97
		EP 0680323 A	08-11-95
		ES 2091712 A	01-11-96
		ES 2100689 T	16-06-97
		WO 9416697 A	04-08-94
		IT 1269185 B	21-03-97
		JP 8505637 T	18-06-96
		LU 88442 A	03-10-94
		NO 952828 A	17-07-95
		NZ 259728 A	28-05-96
		PT 101444 A	31-10-94
		ZA 9400333 A	02-09-94
WO 9629326 A	26-09-96	AU 5333596 A	08-10-96
		EP 0815104 A	07-01-98
WO 9605181 A	22-02-96	AU 3185595 A	07-03-96
		CA 2195972 A	22-02-96
		EP 0777659 A	11-06-97
		ZA 9506757 A	03-04-96
WO 9508549 A	30-03-95	AP 495 A	28-05-96
		AU 681190 B	21-08-97
		AU 7697494 A	10-04-95
		BG 100487 A	31-12-96
		CN 1135218 A	06-11-96
		CZ 9600830 A	11-09-96
		EP 0720609 A	10-07-96
		FI 961270 A	03-05-96
		HR 940575 A	28-02-97
		HU 75648 A	28-05-97
		JP 9505275 T	27-05-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/06692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9508549 A		NO 961156 A	21-05-96
		NZ 273614 A	22-09-97
		PL 313619 A	08-07-96
		SK 38396 A	05-02-97
		US 5703240 A	30-12-97
		ZA 9407291 A	31-05-95
<hr/>			
EP 0577394 A	05-01-94	AU 4156893 A	06-01-94
		AU 4656193 A	24-01-94
		BG 99274 A	30-04-96
		CA 2099233 A	30-12-93
		CN 1087902 A	15-06-94
		CZ 9403330 A	13-09-95
		FI 946133 A	28-12-94
		HR 931003 A	28-02-95
		HU 71809 A	28-02-96
		IL 106142 A	18-03-97
		JP 2634372 B	23-07-97
		JP 6172178 A	21-06-94
		MX 9303888 A	31-03-94
		NO 945064 A	28-02-95
		NZ 254476 A	25-09-96
		SI 9300346 A	31-12-93
		SK 160094 A	11-07-95
		WO 9400440 A	06-01-94
		US 5637699 A	10-06-97
		US 5719147 A	17-02-98
		AU 4160893 A	06-01-94
		ZA 9304624 A	20-06-94
<hr/>			
WO 9518124 A	06-07-95	AU 685209 B	15-01-98
		AU 1322395 A	17-07-95
		BG 100644 A	31-03-97
		BR 9408442 A	05-08-97
		CA 2178219 A	06-07-95
		CN 1139927 A	08-01-97
		CZ 9601898 A	11-12-96
		EP 0737192 A	16-10-96
		HU 75872 A	28-05-97
		JP 9507484 T	29-07-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/06692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9518124 A		LV 11687 B	20-10-97
		NO 962749 A	28-08-96
		PL 315182 A	14-10-96
		SK 83996 A	06-11-96
		US 5612337 A	18-03-97
		ZA 9410317 A	10-10-95
		FI 951762 A	13-10-95
		HR 950222 A	31-08-97

THIS PAGE BLANK (USPTO)